Clinical trials: Ticagrelor
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
Myocardial Infarction
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients
The purpose of the PINPOINT study is to compare pharmacokinetics (PK) and pharmacodynamics (PD) of ticagrelor in ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) patients designated…
- Trial name
- PINPOINT (NCT02602444)
- Testing
- ticagrelor
- Where
- Poland
- Volunteers
- 73 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Dual Antiplatelet Therapy, Platelet Reactivity
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function
- Trial name
- NCT02808039
- Testing
- Platelet reactivity testing
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Myocardial Infarction (MI)
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI).
- Trial name
- STREAMLINE (NCT07507500)
- Testing
- Prasugrel, Ticagrelor
- Where
- 5 sites in Ireland, Latvia and 3 more
- Volunteers
- 8,100 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Stroke, Stroke, Ischemic
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.
- Conditions
- Stroke, Stroke, Ischemic, Atherosclerosis, Myocardial Infarction
- Trial name
- RIISC-THETIS (NCT05476991)
- Testing
- Colchicine 0.5 MG, Ticagrelor 90mg, Aspirin 75-300mg
- Where
- France
- Volunteers
- 2,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atherosclerosis
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation
Ticagrelor and clopidogrel are FDA-approved drugs for inhibition of platelet hyper-reactivity in certain clinical situations. The platelet inhibition and patient outcomes (PLATO) trial showed that in patients with acute coronary…
- Trial name
- NCT02626169
- Testing
- Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
ST-Segment Elevation Myocardial Infarction
Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI) patients receiving percutaneous coronary intervention.
- Trial name
- TIGERCAVE (NCT02123004)
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jinan Central Hospital
Coronary Artery Disease
Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Subjects will be consented to the study prior to Coronary Artery Bypass Graft (CABG) and randomly assigned to receive either ticagrelor 90 mg bid or placebo bid starting within 48 hours of surgery.
- Trial name
- TAP-CABG (NCT01373411)
- Testing
- ticagrelor
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Cardiology Research UBC
Platelet Reactivity
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
The study sought to observe the effects of optimal dose of ticagrelor（90 mg qd）ticagrelor and double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients with high on-treatment platelet reactivity…
- Trial name
- NCT03614832
- Testing
- Ticagrelor 90 mg, Clopidogrel 150 mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Acute Myocardial Infarction, Coronary Artery Disease
Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI
To determine whether, on a background of optimal medical therapy, including ticagrelor, opening of all suitable narrowings or blockages found at the time of primary PCI for an acute heart attack is better than treating only the…
- Trial name
- COMPLETE (NCT01740479)
- Testing
- Complete Revascularization Strategy
- Where
- Canada
- Volunteers
- 4,042 people
- Sponsor
- Population Health Research Institute
Healthy Individuals
Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
Single oral administration of study drugs (i.e. Anplag® \& Brilinta®) in Two periods after at least 10 hours fasting. The periods will be separated by a washout period of 7 days.
- Trial name
- BE (NCT04941196)
- Testing
- Anplag (Ticagrelor 90 mg), Brilinta (Ticagrelor 90 mg)
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Karachi
ACS - Acute Coronary Syndrome, Ticagrelor
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to…
- Conditions
- ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
- Trial name
- FLORA-ACS (NCT07203846)
- Testing
- Rifaximin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Coronary Artery Disease
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with…
- Trial name
- NCT05247385
- Testing
- Prasugrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Ischemic Stroke
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed…
- Trial name
- NCT06591338
- Testing
- Ticagrelor 90 MG, Clopidogrel, Aspirin 75 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Hepatic Artery Thrombosis, Liver Transplant; Complications
Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)
Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet…
- Conditions
- Hepatic Artery Thrombosis, Liver Transplant; Complications, Pediatric Disease
- Trial name
- Tip-HAT (NCT04946929)
- Testing
- Ticagrelor Oral Tablet [Brilinta], Low molecular weight heparin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Chronic Coronary Disease
One-Month DAPT in CABG Patients
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
- Trial name
- ODIN (NCT05997693)
- Testing
- Ticagrelor 90 MG, Low-dose aspirin
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
Coronary Arteriosclerosis
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI
Prasugrel and ticagrelor were both associated with a significant reduction in the risk of MACE in patients undergoing PCI for an ACS, mostly through a reduced stent thrombosis.
- Trial name
- P2BiTO (NCT01967615)
- Volunteers
- 4,500 people
- Sponsor
- G. d'Annunzio University
Stable Coronary Artery Disease
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
- Trial name
- NCT01118325
- Testing
- ticagrelor, clopidogrel
- Where
- 13 sites in Japan, Philippines
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction, Fibrinolysis
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
This is a two-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers (Patras University Hospital and Konstantopoulio…
- Conditions
- ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor
- Trial name
- NCT01950416
- Testing
- Ticagrelor 180mg loading dose and 90mg bid maintenance dose, Clopidogrel 600mg loading dose and 150mg maintenance dose
- Where
- 2 sites in Greece
- Volunteers
- 56 people
- Sponsor
- University of Patras